Showing 6821-6830 of 8649 results for "".
- Researchers Capture Cell-Level Details of Curved Corneahttps://modernod.com/news/researchers-capture-cell-level-details-of-curved-cornea/2478069/Researchers have, for the first time, acquired optical coherence tomography (OCT) images of the curved layers of a person’s cornea with cell-level detail and a large viewing area, according to a study in Optica. The new OCT instrument enables improved monitoring of eye diseases as well a
- Planning ahead: U.S., Canada order 177M more COVID-19 vaccine syringes from BDhttps://modernod.com/news/planning-ahead-u-s-canada-order-177m-more-covid-19-vaccine-syringes-from-bd/2478065/Many countries are working to have the necessary medical infrastructure in place before a
- Study Points to Potential New Approach to Treating Glaucoma and Alzheimer’s Diseasehttps://modernod.com/news/study-points-to-potential-new-approach-to-treating-glaucoma-and-alzheimers-disease/2478060/Researchers at Vanderbilt University Medical Center (VUMC) have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy. In doing so, however, the undamaged optic nerve becomes vu
- Low-Carbohydrate Diet May Be Associated With Lower Risk of Primary Open-Angle Glaucomahttps://modernod.com/news/low-carbohydrate-diet-may-be-associated-with-lower-risk-of-blinding-eye-disease-2/2478047/Following a long-term diet that’s low in carbohydrates and high in fat and protein from vegetables may lower the risk of the most common subtype of glaucoma. In a first-of-its-kind study, a researcher at New York Eye and Ear Infirmary of Mount Sinai (NYEE) helped discover that if at-risk groups a
- Low-Carbohydrate Diet May Be Associated With Lower Risk of Glaucomahttps://modernod.com/news/low-carbohydrate-diet-may-be-associated-with-lower-risk-of-blinding-eye-disease/2478030/Following a long-term diet that’s low in carbohydrates and high in fat and protein from vegetables may lower the risk of the most common subtype of glaucoma. In a first-of-its-kind study, a researcher at New York Eye and Ear Infirmary of Mount Sinai (NYEE) helped discover that if at-risk groups a
- Trump Administration Strips CDC of Control of Coronavirus Datahttps://modernod.com/news/trump-administration-strips-cdc-of-control-of-coronavirus-data/2478021/
- Novavax Gains $1.6 Billion in Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-gains-1-6-billion-in-funding-for-covid-19-vaccine-candidate/2477984/Novavax announced that it has been awarded $1.6 billion by the US government to progress development of NVX CoV2373 and potentially deliver 100 million doses of the COVID-19 vaccine as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using Novavax’s nanop
- Verma: COVID-19 Proving the Need for Greater Interoperabilityhttps://modernod.com/news/verma-covid-19-proving-the-need-for-greater-interoperability/2477988/The COVID-19 pandemic has “exposed a lot of inefficiencies” in the healthcare system—with one of the largest being data sharing and access, Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma said Tuesday, according to a FierceHealthcare
- Hydroxychloroquine Found to Significantly Cut Death Rates in New COVID-19 Studyhttps://modernod.com/news/hydroxychloroquine-found-to-significantly-cut-death-rates-in-new-covid-19-study/2477971/According to a large-scale retrospective analysis published in the International Journal of Infectious Diseases, hydroxychloroquine was associated with a significant decrease in death rate in patients hospitalized with COVID-19, and without heart-related side-effects. Marcus Zervos, division head
- Moderna Reiterates July Start for Phase 3 COVID-19 Vaccine Trial Following Report of Delayhttps://modernod.com/news/moderna-reiterates-july-start-for-phase-3-covid-19-vaccine-trial-following-report-of-delay/2477967/Shares in Moderna fell as much as 9.4% on Thursday after a report indicated that the company’s late-stage trial for potential COVID-19 vaccine mRNA-1273 will be delayed. According to the report in STAT News citing unnamed investigators involved in running the trial, which was slated to begin July